Medical Oncology

, 30:585 | Cite as

TL-118—anti-angiogenic treatment in pancreatic cancer: a case report

  • Shani Breuer
  • Ofra Maimon
  • Liat Appelbaum
  • Tamar Peretz
  • Ayala Hubert
Case Report


Pancreatic cancer is one of the most aggressive malignant tumors. In recent years, little progress has been made in understanding and treatment of the disease. The two most commonly used chemotherapy drugs approved for the treatment of pancreatic cancer are gemcitabine and fluorouracil. Anti-angiogenic treatment is one of the current promising approaches in cancer translational research. Its aim is to inhibit development of new blood vessels and thereby prevent further tumor growth. We present a first description of a pancreatic cancer patient treated with standard chemotherapy and TL-118, an anti-angiogenic combination of 4 drugs that target non-overlapping aspects of the angiogenic process (Provided by Tiltan Pharma Ltd for compassionate use). Our patient, treated with standard chemotherapy combined with TL-118, was diagnosed about 16 months ago and is still considered progression free, while being treated with that combination. Moreover, when the treatment with TL-118 was stopped, there was a clear elevation of tumor marker which dropped again with the renewal of TL-118. This effect was not achieved by gemcitabine treatment alone. Recently, a phase II clinical trial of TL-118 for pancreatic cancer patients that have not yet been treated with chemotherapy was initiated. (Tiltan Pharma Ltd). The study objective is to evaluate the efficacy, safety, and tolerability of TL-118 in gemcitabine-treated metastatic pancreatic cancer patients. This report describes a new approach in treating pancreatic cancer, enabling patients to obtain a longer progression-free survival using this new anti-angiogenic drug combination, added on standard chemotherapy.


Anti-angiogenic TL-118 Pancreatic cancer Gemcitabine 


Conflict of interest

We declare that TL-118, an anti-angiogenic treatment, was provided by Tiltan Pharma Ltd for compassionate use.


  1. 1.
    Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605–17.PubMedCrossRefGoogle Scholar
  2. 2.
    Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W, National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Dhauffert B. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.PubMedCrossRefGoogle Scholar
  4. 4.
    Sonnenblick A, Kadouri L, Appelbaum L, Peretz T, Sagi M, Goldberg Y, Hubert A. Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Cancer Biol Ther. 2011;12(3):165–8. (Epub 2011 Aug 1).PubMedCrossRefGoogle Scholar
  5. 5.
    Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O’Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60(7):1878–86.PubMedGoogle Scholar
  6. 6.
    Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O’Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advancedpancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28(22):3617–22.PubMedCrossRefGoogle Scholar
  7. 7.
    Meyers MO, Watson JC. Angiogenesis and hepatic colorectal metastases. Surg Oncol Clin N Am. 2003;12(1):151–63.PubMedCrossRefGoogle Scholar
  8. 8.
    Murphy JF, Steele C, Belton O, Fitzgerald DJ. Induction of cyclooxygenase-1 and -2 modulates angiogenic responses to engagement of alphavbeta3. Br J Haematol. 2003;121(1):157–64.PubMedCrossRefGoogle Scholar
  9. 9.
    Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Sasaki Y, Kawano S, Hori M. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest. 1999;79(12):1469–77.PubMedGoogle Scholar
  10. 10.
    Burtin C, Noirot C, Scheinmann P, Galoppin L, Sabolovic D, Bernard P. Clinical improvement in advanced cancer disease after treatment combining histamine and H2-antihistaminics (ranitidine or cimetidine). Eur J Cancer Clin Oncol. 1988;24(2):161–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Siegers CP, Andresen S, Keogh JP. Does cimetidine improve prospects for cancer patients? A reappraisal of the evidence to date. Digestion. 1999;60(5):415–21.PubMedCrossRefGoogle Scholar
  12. 12.
    Natori T, Sata M, Nagai R, Makuuchi M. Cimetidine inhibits angiogenesis and suppresses tumor growth. Biomed Pharmacother. 2005;59(1–2):56–60.PubMedCrossRefGoogle Scholar
  13. 13.
    Mayorek N, Naftali-Shani N, Grunewald M. Diclofenac inhibits tumor growth in a murine model of pancreatic cancer by modulation of VEGF levels and arginase activity. PLoS ONE. 2010;5(9):e12715.PubMedCrossRefGoogle Scholar
  14. 14.
    Weber CK, Liptay S, Wirth T, Adler G, Schmid RM. Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000;119(5):1209–18.PubMedCrossRefGoogle Scholar
  15. 15.
    Edrei Y, Gross E, Corchia N, Abramovitch R. Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice. Br J Cancer. 2012;107(4):658–66.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Shani Breuer
    • 1
  • Ofra Maimon
    • 1
  • Liat Appelbaum
    • 2
  • Tamar Peretz
    • 1
  • Ayala Hubert
    • 1
  1. 1.Sharett Institute of OncologyHadassah Hebrew University Medical CenterJerusalemIsrael
  2. 2.Department of Radiology and Medical ImagingHadassah Hebrew University Medical CenterJerusalemIsrael

Personalised recommendations